Two OTC CGMs Cleared; USPSTF Draft Recs for Osteoporosis; Generic Ozempic in Testing

— News and commentary from the endocrinology world

MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

Abbott announced FDA clearance of two over the counter (OTC) : one for adults with type 2 diabetes not on insulin and another for general consumers looking to improve their overall health and wellness.

The on Biomea Fusion's ongoing mid-stage studies of its investigational covalent menin inhibitor BMF-219 for type 1 and type 2 diabetes for possible drug-induced hepatotoxicity.

The U.S. Preventive Services Task Force (USPSTF) is welcoming public comments on its draft recommendation statement for , which advises that all women 65 and over be screened, along with some younger postmenopausal women with osteoporosis risk factors.

At least (Ozempic, Wegovy) are in the final clinical trial stages in China. (Reuters)

Former President Donald Trump is , saying President Biden "had nothing to do with it" despite the $35 price cap for Medicare beneficiaries signed into law in 2022 by Biden. (CNBC)

Adding telephone coaching for individuals with a suboptimal response to an helped patients shed pounds and proved cost-effective. (JAMA Network Open)

In a lawsuit, Roche alleged that counterfeit versions of its ended up on Amazon. (CNBC)

Additional like semaglutide and tirzepatide (Zepbound) may attract more men to use them, five doctors told Reuters.

Dexcom's G7 CGM system can now .

Amid (IVF), Senate Democrats introduced the Right to IVF Act, comprised of four bills aiming to protect IVF and other assisted reproductive technology. (The Hill)

Female nurses who lived in areas with (≥55 dB) had 11% higher odds of obesity. (Environment International)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.